Teva to exit 80 percent generics portfolio in US; Takeda clinches Shire for US$ 62 billion
This week in Phispers, we report on the biggest deal of 2018 yet — Takeda’s acquisition of Shire — that would...
Impressions : 6515
China sees sharp rise in U.S. generic approvals; GSK opts out of Pfizer’s OTC business race
This week,
Phispers brings you news on Pfizer’s OTC auction. After Reckitt Benckiser, even GSK opted out of the race, le...
Impressions : 3737
- Privacy policy
- Terms and conditions
- Disclaimers
-
- Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.